News & Views

  • Collaboration Speeds Commercialisation in Personalised Medicine
    Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area at Qiagen NV.
  • Shunichi Higashi, President and Chief Executive of SRL

Collaboration Speeds Commercialisation in Personalised Medicine

Aug 10 2018 Read 254 Times

A non-exclusive master collaboration agreement between Qiagen and SRL Inc, the largest clinical testing laboratory company in Japan, will accelerate implementation of companion diagnostic workflows following approval of the drugs and tests by Japan’s Pharmaceutical and Medical Devices Agency (PMDA). Several tests are expected to enter registration in Japan in the coming years.

Qiagen’s Day-One Lab Readiness initiative with SRL includes strategic planning for market access to companion diagnostics, filing for reimbursement and alignment of medical communication by the two companies and pharmaceutical partners. The agreement will cover a range of Qiagen companion diagnostics, including real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS) solutions for Personalised Healthcare. Initial projects involve new drugs under development in Japan for solid tumours and leukemia.

“We are pleased to create this innovative program with SRL to close the time gap between new drug approvals and the availability of testing with companion diagnostics. Rapid implementation of personalised medicine solutions can benefit patients in many disease states, including cancer, with treatments guided by personalised genomic insights,” said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area at Qiagen NV.

Shunichi Higashi, President and Chief Executive Officer of SRL, said: “We are excited to partner with QIAGEN to provide new companion diagnostic tests to patients who have urgent need for testing. Through QIAGEN´s numerous companion diagnostic development and commercial collaborations with pharmaceutical companies, we expect a significant increase in commercial testing requests in the upcoming years. Working with QIAGEN will help us to meet these future testing requests in the most timely way for the benefit of patients and healthcare providers in Japan.”

Read comments0

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.


Digital Edition

LabAsia Buyers Guide 2018

October 2018

In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Blue Jacaranda Seed Oil Analysed Using Comprehensive...

View all digital editions

Events

Cleanzone

Oct 23 2018 Frankfurt am Main, Germany

Chem-Lab-Analyt

Oct 29 2018 Moscow, Russia

Lab Innovations 2018

Oct 31 2018 Birmingham, UK

analytica China

Oct 31 2018 Shanghai, China

Lab Expo Tunisia

Oct 31 2018 Tunis, Tunisia

View all events